Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Entegris Inc (ENTG) vs Medpace Holdings Inc (MEDP) Price & Performance

Entegris IncTrade
Medpace Holdings IncTrade

Price performance (Past 24H)

Key statistics

Entegris Inc vs Medpace Holdings Inc — how do they compare? Entegris Inc trades at $160 (market cap $22.95B), while Medpace Holdings Inc trades at $597.39 (market cap $16.90B). The key difference: Entegris Inc is the larger of the two by market cap, and Entegris Inc pays a 0.27% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.

ENTGMEDP
Market Cap
$22.95B$16.90B
Sector
TechnologyTechnology
52-Week High
$184.00$620.59
52-Week Low
$68.80$393.42
Enterprise Value
$26.16B$16.52B
Dividend Yield
0.27%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Entegris Inc

ENTG is trading at $161.18, up 11.77% with strong momentum following three consecutive quarterly earnings beats. The stock shows bullish technical signals with moving averages supporting upward momentum, though RSI suggests mild overbought conditions. Recent Q2 2026 results exceeded expectations with 11% revenue growth and 42% EPS growth driven by AI-related semiconductor demand. Analyst consensus remains strongly positive with 66.7% buy ratings and a $188.67 price target representing 17% upside potential.

The outlook remains favorable given ENTG's positioning in advanced semiconductor materials, with AI-driven demand providing tailwinds. However, elevated valuation multiples (P/E 75.11) and execution risks in capacity expansion warrant monitoring. The company's improving cash flow generation and strong institutional interest support continued growth, though semiconductor cycle sensitivity presents the primary risk to sustained performance.

Medpace Holdings Inc

MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.

MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Entegris Inc

Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.

Read more on ENTG

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP